恒瑞医药(600276.SH)：HRS-4357注射液、HRS-5041片获准开展临床试验

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, which will be conducted shortly [1] Group 1 - The clinical trials will focus on the safety, tolerability, and preliminary efficacy of HRS-4357 in combination with HRS-5041 for the treatment of PSMA-positive prostate cancer [1] - The trials will be open-label, multicenter, and will be conducted in phases Ib/II [1]